REGN vs VRTX
REGN and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | REGNREGENERON PHARMACEUTICALS, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | — | $124.20B |
| P/E (TTM) | 19.2 | 28.5 |
| P/B | — | 6.13 |
| P/S | — | 10.2x |
| Revenue | $15.53B(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 1.0% | 8.9% |
| Net income | $4.33B(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 2.1% | 838.1% |
| EPS, diluted | $40.41(TTM) | $17.17(TTM) |
| EBIT margin | 24.9% | 34.8% |
| ROE | 14.2% | 19.5% |
| ROIC | 9.4% | 25.0% |
| 1y total return | +36.7% | +28.9% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: REGN frente a VRTX
| Métrica | REGN | VRTX |
|---|---|---|
| Valor final | $18.3K | $53.7K |
| Retorno total | +83.1% | +436.8% |
| CAGR | +6.0% | +17.7% |
| Volatilidad | 32.2% | 32.9% |
| Sharpe | 0.22 | 0.54 |
| Sortino | 0.32 | 0.79 |
| Caída máxima | -59.7% | -41.6% |
Basado en 2600 días de negociación comunes, 2016-04-06 → 2026-08-07 · tasa libre de riesgo 3.9% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)